Exploration of Active Site-Directed Plasmin Inhibitors: Beyond Tranexamic Acid

Yuko Tsuda 1,2,*, Koushi Hidaka 1,2, Keiko Hojo 1,2 and Yoshio Okada 1

1 Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Chuo-ku, Kobe 650-8586, Japan; khida@pharm.kobegakuin.ac.jp (K.H.); hojo@pharm.kobegakuin.ac.jp (K.H.); yokada@hb.tp1.jp (Y.O.)
2 Cooperative Research Center for Life Sciences, Kobe Gakuin University, Chuo-ku, Kobe 650-8586, Japan
* Correspondence: tsuda@pharm.kobegakuin.ac.jp; Tel.: +81-78-974-1551

Abstract: Plasmin (Plm), a trypsin-like serine protease, is responsible for fibrinolysis pathway and pathologic events, such as angiogenesis, tumor invasion, and metastasis, and alters the expression of cytokines. A growing body of data indicates that a Plm inhibitor is a potential candidate as an anti-inflammatory and anti-cancer agent. A class of active site-directed plasmin inhibitors containing tranexamic acid residue has been designed. As evidenced by docking studies, the inhibitor binds to the active site not to the lysine binding site (LBS) in plasmin, thus preventing plasmin from digesting the substrate. Further optimization of the series, concerning both activity and selectivity, led to the second generation of inhibitors. This review focuses on the Plm inhibitory activity-structure relationship of Plm inhibitors with the goal of realizing their design and clinical application.

Keywords: active site-directed plasmin inhibitors; serine proteases; tranexamic acid

1. Introduction

Plasmin (Plm), a trypsin-like serine protease, plays a critical role in the fibrinolysis pathway, in which Plm removes intra- and extra-vascularly formed thrombi by degrading fibrin clots. Under normal conditions, Plm circulates in the blood in its zymogen form, plasminogen (Plg), which is a single-chain glycoprotein of 92 kDa [1]. The activation process of Plg to Plm takes place on the surface of fibrin. The C-terminal area of fibrin monomers that are rich in lysine residues facilitates binding to the lysine binding sites (LBS) on the kringle domain of both Plg and tissue Plg activator (tPA) to form fibrin-Plg-tPA complex, which promotes the Plg activation process to generate Plm, having two-chains linked by disulfide bonds [1–5].

On the other hand, a growing consensus indicates that Plm participates in a number of physical processes as well as its dominant role in fibrin cleavage. When Plg is activated by urokinase Plg activator (uPA) on a cell surface, Plm facilitates degradation of the extracellular matrix (ECM) to induce tissue remodeling [6–8], cell inversion, and metastasis [9,10], and other actions, including the activation of the matrix metalloproteases (MMPs). Plm can also bind to a variety of cells, such as monocytes, induce processing of proinflammatory cytokines, and alter the expression of cytokines [11,12]. In fact, we showed that Plm inhibitor, N-(trans-4-aminomethylcyclohexanecarbonyl: TXA)-L-Tyr (OPicolyl)-NH-octyl (YO-2) [13], suppressed the growth of human tumor xenografts and reduced MMP-9-dependent T-cell lymphoid tumor growth [14]. In order to study the precise role of Plm under a disease state, development of selective Plm inhibitors is required. Plm inhibitors may also be potential candidates not only as anti-fibrinolytic agents but also as anticancer and anti-inflammatory agents.

2. Active Site (AS) and LBS-Directed Inhibitors

Today, in the clinical treatment of hyper-fibrinolysis-associated bleeding events, two kinds of Plm inhibitors are applied: aprotinin [15] and lysine analogues, ε-aminocaproic...
acid (EACA) [16] and tranexamic acid (TXA) [17]. Aprotinin is a Kunitz-type serine protease inhibitor against Plm; however, its clinical use has been limited due to several side effects. In contrast, EACA and TXA are widely used. The latter is 10-fold more potent than the former, but high doses of TXA are still necessary (typical efficient doses in human: 1–1.5 g given 3–4 times per day). Recent Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage (CRASH)-2 trials demonstrated that the survival was increased by administration of TXA to a large number of patients with traumatic bleeding [18].

Both inhibitors were discovered by Okamoto et al. from the 1950s to the 1960s. The two agents are surrogates of the amino acid, lysine, and bind to the lysine binding site (LBS) on the kringle domains of Plg, but not to the active site (AS) of Plm. Fibrinolysis is effectively suppressed, as seen in enzyme assays using TXA (IC$_{50}$ = 50 μM), while fibrinogenolysis and amidolysis are hardly suppressed (IC$_{50}$ = 10 mM and Ki = 40 mM, respectively) [19]. This means that, despite the presence of TXA, AS is capable of degrading both fibrinogen and a small substrate. The alternative class of Plm inhibitors, which block the digestion of fibrinogen and a small substrate, may also be required in the clinic. Thus, we have focused on the design of AS-directed Plm inhibitors with the objective of obtaining potent and selective inhibitors to prevent not only fibrinolysis but also amidolysis and fibrinogenolysis.

In this review, development of Plm inhibitors, YO-2 and its derivatives, are described. They showed the Plm inhibitory activity against a chromogenic substrate, demonstrating that they interacted to AS not LBS, in spite of having a TXA moiety in the molecule. Other than YO-2 derivatives, cyclohexane-based inhibitors [20,21], CU2010 [22] and its macrocyclic analogues [23,24], nitrile warheaded inhibitors [25,26], peptide aldehyde-based inhibitors [27], etc., are known as AS-directed Plm inhibitors. This review highlights not only functional but also structural aspects of the YO-related compounds.

3. Design and Synthesis of Substrate-Based Inhibitors

In order to design novel Plm inhibitors, we focused on the structure of the chromogenic substrate, H-D-Ile-Phe-Lys-pNA (1) [28]. We have reported that 1 mildly inhibits Plm fibrinolytic activity (IC$_{50}$ = 180 μM), although 1 itself is a good substrate for Plm (Km = 20 μM). First of all, we prepared H-Lys-pNA derivatives with substitution at the N-terminus of the Lys residue and screened Plm inhibition; the results are summarized in Table 1 [28]. Interestingly, Tos-Lys-pNA (3) was not cleaved by Plm, but did inhibit amidolytic activity (IC$_{50}$ = 700 μM against S-2251) as well as fibrinolytic activity (IC$_{50}$ = 780 μM). For the purpose of obtaining lysine derivatives that are not susceptible to Plm, we replaced the p-nitroanilide group with more hydrophobic amides such as 4-benzylpiperedineamide (BPP), 4-benzoxylanilide (BZA), or 4-acetylanilide (ACA). Their effects on Plm are summarized in Table 2 [28]; replacement increased the Plm inhibition not only of amidolytic activity by some 3- to 5-fold but also of fibrinolytic activity by some 5-fold.

| Comp. | IC$_{50}$ (μM) | S-2251 | Fibrin |
|-------|---------------|--------|--------|
| 1     | (Km = 20 μM)  | 180    |        |
| 2     | (Km = 200 μM) | 250    |        |
Table 1. Cont.

| Comp. | S-2251 (µM) | Fibrin (µM) |
|-------|-------------|-------------|
| 3     | 700         | 780         |

S-2251: H-D-Val-Leu-Lys-pNA.

Table 2. Plm inhibitory activity of compounds 4–10 [28].

| Comp. | IC₅₀ (µM) | S-2251 | Fibrin |
|-------|-----------|--------|--------|
| 4     | 300       | 150    |        |
| 5     | 210       | 100    |        |
| 6     | 3,000     | 2,100  |        |
| 7     | 140       | 150    |        |
| 8     | >100      | >25    |        |
| 9     | 69        | 180    |        |
| 10    | 210       | 250    |        |

S-2251: H-D-Val-Leu-Lys-pNA.

Tos-Lys-BZA (7: IC₅₀ = 140 and 150 µM for S-2251 and fibrin, respectively) hydrolyzed a small chromogenic substrate, S-2251, more strongly compared with TXA (IC₅₀ = 75,000 and 60 µM for S-2251 and fibrin, respectively), demonstrating that 7 was an AS-directed Plm inhibitor rather than an LBS-directed inhibitor.
4. Substitution of P2, P1 and P1′ Residues

4.1. Incorporation of TXA

On referring to the structure of 7, each part of the Tos, Lys, and BZA moieties was replaced with various moieties: Lys, EACA, TXA, and cis-4-aminocyclohexycarboxylic acid instead of Tos (Table 3); D-Lys and ornithine instead of Lys (Table 4); and ACA, 4-benzoylphenyl ester, BPP instead of BZA (Table 5). In this series (Tables 3–5) [29], H-TXA-Lys-BZA (13: IC$_{50}$ = 15 and 6.1 µM for S-2251 and fibrin, respectively) and H-TXA-Lys-ACA (17: IC$_{50}$ = 39 and 9.3 µM for S-2251 and fibrin, respectively) exhibited strong Plm inhibition. The main question that arises from this result is: which amino group (TXA or Lys in H-TXA-Lys-4-benzoylphenoxymethyl ketone (13) interacts with Asp at the S1 site, and the new series of Plm inhibitors, having a sequence of (P1-P2-P1′)?, in which P1 was a TXA residue, was proposed.

Table 3. Plm inhibitory activity of compounds 11–14 [29].

| Comp. | R: | IC$_{50}$ (µM) |
|-------|-----|----------------|
| 11    | H$_{2}$N | 16  | 17  |
| 12    | H$_{2}$N | 12  | >10 (18%) |
| 13    |  | 15  | 6.1 |
| 14    |  | 400 | 260 |

4.2. Switch from Lys to Phe/Tyr

Starting from H-TXA-Lys-ACA (17), Lys and ACA moieties were converted to various moieties; Phe and Tyr (2-BrZ) were used as an alternative to Lys and 4-carboxymethylanilide and octylamide were used as an alternative to ACA. The structure-inhibitory activity relationships are summarized in Table 6 [30]. H-TXA-Phe-ACA (23: IC$_{50}$ = 36 and 21 µM for S-2251 and fibrin, respectively) shows Plm inhibition corresponding to that of 17. This means that the Lys residue is replaceable by a Phe residue. The enhanced inhibition on compounds 24, 25, and 26 indicated that an additional phenyl ring of Bzl, Z, and Br-Z may be acceptable at the S1′ site of Plm. In the new series, H-TXA-Tyr (2-BrZ)-ACA (26) was the most potent Plm inhibitor; however, it inhibited not only Plm (IC$_{50}$ = 0.23 µM for S-2251), but also plasma kallikrein (PK: IC$_{50}$ = 0.37 µM), uPA (IC$_{50}$ = 43 µM), and thrombin (Thr: IC$_{50}$ = 63 µM).
Table 4. Plm inhibitory activity of compounds 13 [29], 15 [29], and 16 [29].

| Comp. | R: | IC₅₀ (μM) | S-2251 | Fibrin | Fibrinogen |
|-------|----|-----------|--------|--------|------------|
| TXA   |    | 75,000    | 60     | 9,500  |            |
| 13    |    | 15        | 6.1    | 13     |            |
| 15    |    | >200 (0%) | >200 (0%) | ND     |            |
| 16    |    | >300 (33%)| >300 (43%) | ND     |            |

S-2251: H-D-Val-Leu-Lys-pNA; ND: Not determined.

Table 5. Plm inhibitory activity of compounds 17–19 [29].

| Comp. | R: | IC₅₀ (μM) | S-2251 | Fibrin |
|-------|----|-----------|--------|--------|
| 13    |    | 15        | 6.1    |
| 17    |    | 39        | 9.3    |
| 18    |    | 24        | 170    |
| 19    |    | >500 (7%) | >500 (16%) |

S-2251: H-D-Val-Leu-Lys-pNA.
Processes 2021, 9, 329

Figure 1. Confirmation of which amino acid interacts with Asp at the S1 site by using two derivatives (21 [29] and 22 [29]) from 20 [29].

Table 6. Inhibitory activity of compounds 23–26 [30] against various proteases.

| Comp. | R: | IC50 (µM) | Plm | PK | uPA | Thr |
|-------|----|-----------|-----|----|-----|-----|
|       |    |           | S-2251 | S-2302 | S-2444 | S-2238 |
| 23    |    |           | 36   | 21  | 0.85 | 58  | >1000 |
| 24    |    |           | 1.8  | 0.40 | 0.63 | 31  | >200 (10%) |
| 25    |    |           | 0.64 | 0.29 | 0.58 | 45  | >100 (11%) |
| 26    |    |           | 0.23 | 0.051 | 0.37 | 43  | 63  |

S-2251: H-D-Val-Leu-Lys-pNA; S-2302: H-D-Pro-Phe-Arg-pNA; S-2444: pyroGlu-Gly-Arg-pNA; S-2238: H-D-Phe-Pip-Arg-pNA.

4.3. Discovery of H-TXA-Tyr(2-BrZ)-NH-Octyl (36, YO-2)

To improve selectivity for Plm, the ACA moiety was modified with branched and unbranched alkylamides, p-alkylanilides, pyridineanilides, and pyridinealkylanilides [31]. As far as the P2' substituent is concerned, increasing the alkyl chain length resulted in enhanced inhibitory activity against Plm but reduced inhibition for PK and uPA (compounds 27–29: Table 7). Compounds 27–29, bearing unbranched alkylamides, strongly and selectively inhibited Plm, but compound 30, having a branched alkylamide, strongly inhibited Plm as well as PK. Furthermore, the introduction of an aromatic ring into the P2' enhanced the PK inhibition rather than the Plm inhibition (compounds 31–34: Table 7), meaning that the bulkiness of S2' sub-sites of Plm and PK was quite different. The above compounds had low solubility in an aqueous solution due to the hydrophobic property of the 2-BrZ moiety. To overcome this disadvantage, the 2-BrZ moiety was substituted with 4-methoxycarboxybenzol, 4-pyridylmethyl (Pic) and 4-pyridineacethyloxycarbonyl to yield compounds 35–37 (see Table 8) [13]. All things considered, we decided to use compound 36 (YO-2) as a lead of Plm specific inhibitor; 36 inhibited Plm (IC50 = 0.53 µM) but hardly affected PK (IC50 = 30 µM) and Thr (IC50 > 400 µM). However, 36 also retained uPA inhibition (IC50 = 5.3 µM), meaning that 36 lost specificity (Plm/uPA) to a limited but small degree.
Table 7. Inhibitory activity of compounds 27–34 [31] against various proteases.

| Comp. | R: | IC<sub>50</sub> (μM) |
|-------|----|---------------------|
|       |    | Plm | PK | uPA | Thr |
|       |    | S-2251 | S-2302 | S-2444 | S-2238 |
| 27    | H-  | 1.1  | 0.43 | 10  | >50 |
| 28    | H-  | 0.80 | 0.23 | 16  | 50  | >50 |
| 29    | H-  | 0.50 | 0.10 | 22  | >10 | 100 |
| 30    | H-  | 0.46 | 0.056 | 2.1 | 260 | 70  |
| 31    | H-  | 0.63 | 0.098 | 0.71 | >50 | 89  |
| 32    | H-  | 1.1  | 0.30 | 7.0 | >50 | >50 |
| 33    | H-  | 0.98 | 0.17 | 0.29 | 19  | 91  |
| 34    | H-  | 5.3  | 1.40 | 14.0 | 72  | 240 |

S-2251: H-D-Val-Leu-Lys-pNA; S-2302: H-D-Pro-Phe-Arg-pNA; S-2444: pyroGlu-Gly-Arg-pNA.

Table 8. Inhibitory activity of compounds 28 [31] and 35–37 [13] against various proteases.

| Comp. | R: | IC<sub>50</sub> (μM) |
|-------|----|---------------------|
|       |    | Plm | PK | uPA |
|       |    | S-2251 | S-2302 | S-2444 |
| 28    | H-  | 0.80 | 16  | >50 |
| 35    | H-  | 0.65 | 38  | >50 |
| 36    | H-  | 0.53 | 30  | 5.3 |
| 37    | H-  | 1.0  | 12  | 31  |

S-2251: H-D-Val-Leu-Lys-pNA; S-2302: H-D-Pro-Phe-Arg-pNA; S-2444: pyroGlu-Gly-Arg-pNA.

5. Improvement of Specificity (Plm/uPA)

For the further development of specific inhibitors, docking experiments with the μPlm-36 (YO-2) complexes were performed, and the results are as follows [32]: the TXA moiety was located in the S1 site where its amino group formed polar interaction with the carboxyl group of Asp; the Tyr(OPic) laid along the hydrophobic S2 wall and the extra S2 site in an extend conformation; the octylamide moiety was oriented toward the hydrophobic region in the S1′ pocket [32]. The docking positions suggested that 36 (YO-2) with the μPlm acquired a tripod shape (P2-P1-P1′), in which polar interactions between
the amino moiety of TXA and the side chain of Asp in the S1 pocket and with additional hydrophobic contacts at the S2, extra S2, and S1’ pockets produced the high inhibitory activity of 36 (YO-2).

A number of trypsin-like serine proteases have a common Asp residue in the bottom of the S1 pocket; however, there are also other secondary sites located from the S2 to S3/S4 of the sub-sites. Structural differences at the secondary sites among those enzymes do exist. In Plm, the secondary binding pocket, S2/S3, is widely open due to the absence of the loop segment 95–100 (corresponding to the chymotrypsin-numbering). On the other hand, in uPA, the size of S2/S4 is greatly reduced because of an insertion of the loop segment 95–100, which obstructs both sites. Regarding the differences within the secondary sites, S2/S3 sub-site, Saupe and Steinmetzer designed the macrocyclic CU2010 analogues, which occupies the larger binding groove apart from the primary binding pocket to specifically inhibit Plm [23,24]. Similarly, extension of the hydrophobic substituents in the Tyr residue of 36 may generate Plm specific inhibitors.

Based on the above concept, the P2 residues were explored [33]. All compounds (38–41) having the hydrophobic extension on P2 residue inhibited Plm with IC50 values in the μM range (0.22–0.75 μM), while inhibiting uPA more moderately (IC50 values 77 to >200 μM) (Table 9). Compound 39, containing an O-(quinolin-2-yl)methyl moiety, exhibited the highest and most Plm selective inhibition (IC50 = 0.22 and 77 μM for Plm and uPA).

### Table 9. Inhibitory activity of compounds 38–41 [33] against various proteases.

| Comp. | R: | IC50 (μM) |
|-------|----|-----------|
|       | Plm | uPA | trypsin |
| S-2251 | S-2444 | S-2238 |
| 38 | H-D-Val-Leu-Lys-pNA | 0.34 | >100 | 93 |
| 39 | S-2444: pyroGlu-Gly-Arg-pNA; S-2238: H-D-Phe-Pip-Arg-pNA. | 0.22 | 77 | 1.4 |
| 40 | | 0.97 | >50 | 1.3 |
| 41 | | 0.75 | >100 | 6.7 |

Further, our docking studies with the μPlm-39 complexes revealed that 39 bound with μPlm in a similar manner to 36 (YO-2): the TXA inserted into the bottom of the S1 site; the quinoline ring lay on the hydrophobic region of the S2 and extra S2 groove; the octyl residue contributed to the additional hydrophobic interactions [33].

### 6. X-ray Crystal Structures of 35 and 39 in the Complex with μPlm

The co-crystal structures of 39 in the complex with μPlm [34] revealed an unexpected binding mode in which the TXA residue goes straight into the primary binding site (S1 site). In addition, the double aromatic rings occupy other secondary binding sites (the S1’ and S3’ sites) in particular to make extensive interactions at the S3’ subsite where the pyridine ring of the quinolin moiety takes a perfect face-to-edge CH- stacking with Phe587. A larger P3’ residue would be acceptable by the S3’ site of Plm. Additionally, a number of different possible binding forms between 39 and Lys607 are observed by the electron density map. Surprisingly, the hydrophobic octyl residue has no interaction with the S2’ pocket; on the contrary, it point away from the surface of the protease. Although 36 (YO-2) with μPlm reveals a similar binding mode to 39 at the primary binding site, the pyridine ring of
the picolyl moiety forms an imperfect face-to-face-stacking with Phe587 [34]. Compared with amino acid sequence of Plm and uPA, first, Phe587 is replaced with Val181 in uPA and, second, the equivalent position to Lys607 is Asp208 in uPA. Ruby et al. argue that those replacements may interfere with the binding of 39 to reduce the uPA inhibitory activity (Figure 2).

Figure 2. Tranexamic acid (TXA) derivatives bond with μPlm. (A) Binding orientation of 36 (green stick, pdb 5ugg) and 39 (orange stick, pdb 5ugg) at the sub-site S1 to S1′, S2′, and S3′; (B) Picolyl and quinolinyl moieties extended from Tyr side chain in the S3′ pocket; (C) Superimposition of the active sites of μPlm (white molecular surface, pdb 5ugd) and uPA (magenta molecular surface, pdb 1fv9); (D) Close up view of the S3′ pockets; The quinoline moiety collides with both Tyr209 and Arg178 residues of at the S3′ site of uPA. *The numbers of amino acid residues correspond to full-length Plm or uPA.

7. Challenge for Application beyond TXA

The data that 36 suppresses matrix metalloproteinase 9-mediated cytokine release to protect colitis in mice [35] and prevents macrophage activation syndrome in a murine model [36] are discussed relative to the various functions of Plm. However, the biological properties of 39 have not been determined.

Independently, Bristol-Myers Squibb (BMS) reported the discovery of compound 40 [37], which contains TXA and phenylalanine (Phe) residues, comparable to that of 36 and 39. The dual inhibition of Plm and FXa was shown for 40 (Ki = 8.4 and 0.0003 μM for Plm and FXa, respectively) [37,38]. Based on the structure of 40, the development of orally bioavailable FXa inhibitors (41, 42) is progressing at BMS [39,40] (Figure 3). Bayer AG investigated other analogues of Plm inhibitors containing both TXA and side-chain extended Phe residues. For example, compound 43 elongated at the para position of Phe and at the C-terminal heterocycle moiety and exhibited dual inhibition (IC50 = 0.32 and 3.5 nM for Plm and FXa, respectively) [41] (Figure 4). Steinmetzer et al. discussed the similar molecular alteration in their review [42]. Bayer AG derivatives are currently being
evaluated for their pharmacokinetics and pharmacodynamics properties, and for safety for eventual application in antithrombotic therapy.

![Figure 3. Structure of compounds 40–42 [37–40] developed by Bristol-Myers Squibb (BMS).](image)

![Figure 4. Structure of compound 43 [41] developed by Bayer AG.](image)

8. Conclusions

To seek active site-directed Plm inhibitors, substrate H-D-Ile-Phe-Lys-pNA (1) was engineered into H-TXA-Tyr(OPic)-NH-Octyl (36, YO-2), which inhibited Plm (IC₅₀ = 0.53 μM) and uPA (IC₅₀ = 5.3 μM), but only weakly inhibited PK (IC₅₀ = 30 μM) and Thr (IC₅₀ > 400 μM). Following various explorative studies, the TXA residue (as a primary contacting moiety) and Tyr(OPic) residue (as a secondary contacting moiety) led to the development of 36. Considering the difference of the secondary binding site between Plm and uPA, 36 was further engineered to H-TXA-Tyr(O-(quinolin-2-yl)methyl)-NH-Octyl (39), which showed similar inhibitory activity to that of 36 with a significant improvement in selectivity (Plm/uPA) by 35-fold. The crystal structures of 36 and 39 disclose that the TXA residue in both 36 and 39 interacts to the primary site, the S1 site, as well as to the secondary sites, S1′, S2′, and S3′. Those crystal structures might provide comprehension for a rational approach to developing new compounds.

**Author Contributions:** Conceptualization, Y.T. and Y.O.; analysis and visualization of co-crystal structure, K.H. (Koushi Hidaka); writing—review and editing, Y.T., with the assistance of K.H. (Koushi Hidaka); review and editing, Y.O.; K.H. (Koushi Hidaka) and K.H. (Keiko Hojo). All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the Ministry of Education, Science, Sports, and Culture of Japan, Grant-in-Aid of Scientific Research “C, 25460164” and Grant-in-Aid of Scientific Research “C, 16K08333”.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Acknowledgments:** The work was supported by Grant-in-Aid of Scientific Research (C, 25460164/2013-2015) and Grant-in-Aid of Scientific Research (C, 16K08333/2016-2018) from the Ministry of Education, Science, Sports, and Culture of Japan. The authors express deep thanks to Lawrence H. Lazarus for his kind help in the preparation of the manuscript.

**Conflicts of Interest:** The authors declare no conflict of interest.
27. Swedberg, J.E.; Harris, J.M. Plasmin substrate binding site cooperativity guides the design of potent peptide aldehyde inhibitors. *Biochemistry* 2011, 50, 8454–8462. [CrossRef]

28. Okada, Y.; Tsuda, Y.; Teno, N.; Wanaka, K.; Bohgaki, M.; Hijiikata-Okunomiya, A.; Naito, T.; Okamoto, S. Synthesis of active center-directed peptide inhibitors of plasmin. *Chem. Pharm. Bull.* 1988, 36, 1289–1297. [CrossRef]

29. Teno, N.; Wanaka, K.; Okada, Y.; Tsuda, Y.; Okamoto, U.; Hijiikata-Okunomiya, A.; Naito, T.; Okamoto, S. Development of active center-directed inhibitors against plasmin. *Chem. Pharm. Bull.* 1991, 39, 2340–2346. [CrossRef] [PubMed]

30. Teno, N.; Wanaka, K.; Okada, Y.; Taguchi, H.; Okamoto, U.; Hijiikata-Okunomiya, A.; Okamoto, S. Development of active center-directed plasmin and plasma kallikrein inhibitors and studies on the structure-inhibitory activity relationship. *Chem. Pharm. Bull.* 1993, 41, 1079–1090. [CrossRef]

31. Okada, Y.; Matsumoto, Y.; Tsuda, Y.; Tada, M.; Wanaka, K.; Hijiikata-Okunomiya, A.; Okamoto, S. Development of plasmin-selective inhibitors and studies of their structure-activity relationship. *Chem. Pharm. Bull.* 2000, 48, 184–193. [CrossRef]

32. Gohda, K.; Teno, N.; Wanaka, K.; Tsuda, Y. Predicting subsite interactions of plasmin with substrates and inhibitors through computational docking analysis. *J. Enzym. Inhib. Med. Chem.* 2012, 27, 571–577. [CrossRef]

33. Hidaka, K.; Gohda, K.; Teno, N.; Wanaka, K.; Tsuda, Y. Active site-directed plasmin inhibitors: Extension on the P2 residue. *Bioorg. Med. Chem.* 2016, 24, 545–553. [CrossRef] [PubMed]

34. Law, R.H.P.; Wu, G.; Leung, E.W.W.; Hidaka, K.; Quek, A.J.; Caradoc-Davies, T.T.; Jeevarajah, D.; Conroy, P.J.; Kirby, N.M.; Norton, R.S.; et al. X-ray crystal structure of plasmin with tranexamic acid-derived active site inhibitors. *Blood Adv.* 2017, 1, 766–771. [CrossRef]

35. Munakata, S.; Tashiro, Y.; Nishida, C.; Sato, A.; Komiyama, H.; Shimazu, H.; Dhahri, D.; Salama, Y.; Eiamboonsert, S.; Takeda, K.; et al. Inhibition of plasmin protects against colitis in mice by suppressing matrix metalloproteinase 9-mediated cytokine release from myeloid cells. *Gastroenterology* 2015, 148, 565–578.e4. [CrossRef] [PubMed]

36. Shimazu, H.; Munakata, S.; Tashiro, Y.; Salama, Y.; Dhahri, D.; Eiamboonsert, S.; Ota, Y.; Onoda, H.; Tsuda, Y.; Okada, Y.; et al. Pharmacological targeting of plasmin prevents lethality in a murine model of macrophage activation syndrome. *Blood* 2017, 130, 59–72. [CrossRef] [PubMed]

37. Hangeland, J.J.; Friend, T.J.; Rossi, K.A.; Smallheer, J.M.; Wang, C.; Sun, Z.; Corte, J.R.; Fang, T.; Wong, P.C.; Rendina, A.R.; et al. Phenylimidazoles as potent and selective inhibitors of coagulation factor XIa with in vivo antithrombotic activity. *J. Med. Chem.* 2014, 57, 9915–9932. [CrossRef]

38. Corte, J.R.; Fang, T.; Hangeland, J.J.; Friend, T.J.; Rendina, A.R.; Rossi, K.A.; Wei, A.; Ramamurthy, V.; Morin, P.E.; Seiffert, D.A.; et al. Pyridine and pyridinone-based factor XIa inhibitors. *Bioorg. Med. Chem. Lett.* 2015, 25, 925–930. [CrossRef]

39. Clark, C.G.; Rossi, K.A.; Corte, J.R.; Fang, J.M.; Smallheer, J.M.; De Lucca, I.; Nirschl, D.S.; Orwat, M.J.; Pinto, D.J.P.; Hu, Z.; et al. Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability. *Bioorg. Med. Chem. Lett.* 2019, 29, 126604. [CrossRef]

40. Corte, J.R.; Pinto, D.J.P.; Fang, T.; Osuna, H.; Yang, W.; Wang, Y.; Lai, A.; Clark, C.G.; Sun, J.H.; Rampulla, R.; et al. Potent, orally bioavailable, and efficacious macrocyclic inhibitors of factor XIa. Discovery of pyridine-based macrocycles possessing phenylazole carbamoyl P1 groups. *J. Med. Chem.* 2020, 63, 784–803. [CrossRef]

41. Roehn, U.; Ellermann, M.; Strassburger, J.; Wendt, A.; Roehrig, S.; Webster, R.A.; Schmidt, M.V.; Tersteegen, A.; Bayer, K.; Schaefer, M.; et al. Preparation of substituted phenylalanine derivatives as FXa modulators for treating thrombotic and thromboembolic diseases. WO2015044163A1, 2015.

42. Steinmetzer, T.; Pilgram, O.; Wenzel, B.M.; Wiedemeyer, S.J.A. Fibrinolysis inhibitors: Potential drugs for the treatment and prevention of bleeding. *J. Med. Chem.* 2020, 63, 1445–1472. [CrossRef]